MPS Limited has announced that the unpaid final dividend for the financial year 2018-19 will be transferred to the Investor Education and Protection Fund (IEPF) on August 30, 2026. The company stated that the transfer is in accordance with Section 124(6) of the Companies Act, 2013, and the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. This action follows a public notice published in the Financial Express and Makkal Kural on May 28, 2026, inviting shareholders to submit their claims.

The company has specifically warned shareholders whose dividends have remained unpaid or unclaimed for seven consecutive years. For these shareholders, the underlying equity shares will also be transferred to the IEPF. Once transferred, all voting rights attached to these shares will be frozen, and shareholders will lose all future benefits, including dividends, bonus shares, splits, and consolidations. No claim shall lie against the company in respect of shares or unclaimed dividends transferred to IEPF pursuant to the rules.

Shareholders are requested to claim their unclaimed dividends on or before August 28, 2026. If the company does not receive communication from the concerned shareholders by this date, it will proceed to transfer the equity shares to the IEPF without further notice. All future dividends on these transferred shares will be credited directly to the IEPF.

Key Dates and Deadlines

The complete list of shareholders whose dividends are unpaid for seven consecutive years and whose shares are liable for transfer is available on the company’s website under the Investors Section. The company has already communicated with these shareholders via letters. Shareholders can claim back transferred dividends and shares from the IEPF authority by following the procedures prescribed on the IEPF website. For any information or clarification, shareholders may contact wisdom.cameoindia.com or investors@mpslimited.com .

MPS Limited reported its audited standalone and consolidated financial results for the fourth quarter and financial year ended 31 March 2026. The company posted a record consolidated Basic EPS of ₹102.11 for FY26, an increase of 16.3% year-over-year. Consolidated revenue from operations for the full year stood at ₹76,837 lacs, up from ₹72,689 lacs in the previous year. The statutory auditors, M/s. Walker Chandiok & Co LLP, issued an unmodified audit report for the quarter and year ended 31 March 2026. The Board of Directors approved the results at its meeting held on 15 May 2026.

Consolidated Financial Performance

On a consolidated basis, the company delivered strong performance across both the quarter and the full year. Total comprehensive income for the year rose to ₹20,313 lacs from ₹15,256 lacs in FY25. Q4 FY26 EBITDA improved to ₹675M from ₹560M in Q4 FY25, with the EBITDA margin expanding to 32.90% from 30.76%. The Research segment reported a Q4 EBITDA margin of 41.59%, acting as the highest-margin engine. The following table presents the key consolidated financial metrics:

Standalone Financial Performance

On a standalone basis, revenue from operations for Q4 stood at ₹11,931 lacs compared to ₹9,371 lacs in the corresponding quarter of the previous year. For the full year, standalone revenue from operations reached ₹43,826 lacs, up from ₹35,134 lacs in FY25. Standalone profit before tax for the full year was ₹16,894 lacs compared to ₹14,516 lacs in the previous year. The standalone Equity Share Capital stood at ₹1,711 lacs and Other Equity at ₹38,125 lacs as on 31 March 2026.

Segment Performance

The Group operates across three business segments: Research Solutions, Education Solutions, and Corporate Learning. Research Solutions remained the anchor with reported revenue of ₹46,351 lacs for FY26, while Education Solutions contributed ₹20,890 lacs and Corporate Learning contributed ₹9,596 lacs. Education Solutions accounted for 29.3% of the Q4 revenue mix. The following table summarises segment-wise performance for FY26 and FY25:

Key Corporate Developments

MPS Limited completed the acquisition of 100% stake in Unbound Medicine, Inc., USA through MPS North America LLC on 9 February 2026, for a total consideration of USD 16.50 million (subject to customary adjustments). The acquisition was funded through a combination of internal accruals and external borrowings of ₹4,200 lacs, with provisional goodwill of ₹12,386 lacs recognised on a preliminary purchase price allocation basis. In view of the capital deployed for this acquisition, the Board decided not to recommend a final dividend for FY26. Total exceptional items (net) for FY26 amounted to a net gain of ₹764 lacs, comprising restructuring costs of the American Journal Experts business, incremental labour code impacts, write-back of liabilities related to the Liberate Group acquisition, an impairment loss on goodwill of ₹1,293 lacs, and a write-back of ₹1,395 lacs pursuant to a change in policy on customer advances in the AJE business. The Board also approved a draft Scheme of Amalgamation for the merger of ADI BPO Services Limited with MPS Limited, which has been filed before the NCLT, Chennai Bench, and is presently awaiting hearing.

Corporate Governance and Regulatory Compliance

The Board approved the re-appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a second term of five consecutive years, commencing from the conclusion of the ensuing 56th Annual General Meeting until the conclusion of the 61st AGM to be held in the calendar year 2031, subject to shareholder approval. Additionally, M/s. KPMG Assurance and Consulting Services LLP were appointed as Internal Auditors for a term of three consecutive financial years commencing from Financial Year 2026-27 up to Financial Year 2028-29, for both the Company and its material subsidiary, MPS Interactive Systems Limited. Subsequent to the quarter ended 31 March 2026, the Nomination and Remuneration Committee approved the 5th grant of 79,009 options to eligible employees under the MPS Limited Employee Stock Options Scheme 2023.

Management Commentary and Outlook

During the earnings conference call held on 18 May 2026, management stated that FY26 closed as the most profitable year in the company's history, with EBITDA of ₹236 crores and an EBITDA margin of 30.7%. The company has issued guidance for FY27 EBITDA of ₹300+ crores, implying a 3-year EBITDA CAGR of approximately 21% from FY24 to FY27. Management noted that Q4 was the strongest quarter of the year, with revenue growing 12.7% year-over-year to ₹205 crores and EBITDA growing 20.5% to ₹67.5 crores. The guidance is built bottom-up from the operating plans of each business segment and reflects organic growth, excluding new acquisitions other than Unbound Medicine.